Alecensa 150 mg Alternative – Alecnib (Alectinib) 150 mg Capsule | Everest Pharmaceuticals
Alecnib 150 mg (Alectinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Alecensa (Roche / Genentech). It belongs to the ALK inhibitor class and is used in appropriately tested ALK-positive non-small cell lung cancer.
Active ingredient: Alectinib
Strength: 150 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Alunbrig 180 mg Alternative – Brigacent (Brigatinib) 180 mg Tablet | Incepta Pharmaceuticals
Brigacent 180 mg (Brigatinib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Alunbrig (Takeda).
Pack: 7 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Alunbrig 90 mg Alternative – Brigacent (Brigatinib) 90 mg Tablet | Incepta Pharmaceuticals
Brigacent 90 mg (Brigatinib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Alunbrig (Takeda).
Pack: 7 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Gilotrif 40 mg Alternative – Afatin (Afatinib) 40 mg Tablet | Beacon Pharmaceuticals
Iressa 250 mg Alternative – Geficent (Gefitinib) 250 mg Tablet | Incepta Pharmaceuticals
Geficent 250 mg (Gefitinib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Iressa (AstraZeneca).
Pack: 10 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Iressa 250 mg Alternative – Gefinix (Gefitinib) 250 mg Tablet | Beacon Pharmaceuticals
Lorbrena / Lorviqua 100 mg Alternative – Lorbrexen (Lorlatinib) 100 mg Tablet | Everest Pharmaceuticals
Lorbrexen 100 mg (Lorlatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lorbrena / Lorviqua (Pfizer). It belongs to the ALK inhibitor class and is used in selected ALK-positive metastatic non-small cell lung cancer.
Active ingredient: Lorlatinib
Strength: 100 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Lumakras / Lumykras 120 mg Alternative – Sotoxen (Sotorasib) 120 mg Tablet | Everest Pharmaceuticals
Sotoxen 120 mg (Sotorasib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lumakras / Lumykras (Amgen). It belongs to the KRAS G12C inhibitor class and is used in selected KRAS G12C-mutated non-small cell lung cancer.
Active ingredient: Sotorasib
Strength: 120 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Retevmo / Retsevmo 40 mg Alternative – Selcaxen (Selpercatinib) 40 mg Capsule | Everest Pharmaceuticals
Selcaxen 40 mg (Selpercatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Retevmo / Retsevmo (Eli Lilly). It belongs to the RET inhibitor class and is used in selected RET-altered lung or thyroid cancers.
Active ingredient: Selpercatinib
Strength: 40 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Tabrecta 200 mg Alternative – Capmaxen (Capmatinib) 200 mg Tablet | Everest Pharmaceuticals
Capmaxen 200 mg (Capmatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Tabrecta (Novartis). It belongs to the MET inhibitor class and is used in selected MET exon 14 skipping non-small cell lung cancer.
Active ingredient: Capmatinib
Strength: 200 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Tagrisso 80 mg Alternative – Osicent (Osimertinib) 80 mg Tablet | Incepta Pharmaceuticals
Osicent 80 mg (Osimertinib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Tagrisso (AstraZeneca).
Pack: 10 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Tagrisso 80 mg Alternative – Osimert (Osimertinib) 80 mg Tablet | Everest Pharmaceuticals
Osimert 80 mg (Osimertinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Tagrisso (AstraZeneca). It belongs to the EGFR tyrosine kinase inhibitor class and is used in selected EGFR-mutated non-small cell lung cancer.
Active ingredient: Osimertinib
Strength: 80 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.